Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HPP

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

National Institute for Health and Care Excellence NICE logo

Another NICE no for AZ’s new ovarian cancer drug

Cost watchdog wants more information for Lynparza

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

NHS England proposes handing CDF remit to NICE

Comes after a difficult two years for the silo budget

- PMLiVE

NICE backs Bayer’s Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

National Institute for Health and Care Excellence NICE logo

NICE no for new eye disease drug

Institute says ‘gaps and uncertainties’ in the treatment’s evidence directed its decision

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Patient survey finds pharma falls short on drug pricing

The industry is coming under increasing attack from all sides as price tags rise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links